Drug-Intervention Lag Phase Between Low-Density Lipoprotein-Cholesterol Lowering and Coronary Plaque Stabilization Authors: Norihito Takahashi, Hiroshi Iwata Published: 2026 Intensive lowering of low-density lipoprotein cholesterol (LDL-C) with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors added to statins and ezetimibe has become central to secondary prevention in coronary artery disease (CAD), supported by randomized trials showing robust reductions in cardiovascular events.1 These findings shaped the “strike early and strong” paradigm, advocating early, intensive, upfront combination therapy to minimize cumulative atherogenic burden.2 Yet rapid LDL-C lowering does not necessarily indicate immediate stabilization of all high-risk plaques. Article p 1379 In this issue of the Journal, Miura et al. present a clinically instructive case of acute coronary syndrome (ACS).3 In a patient with heterozygous familial hypercholesterolemia, rosuvastatin plus evolocumab lowered LDL-C to 51 mg/dL after PCI, yet ACS recurred 7 months later from a distal lesion where serial optical coherence tomography showed persistent thin-cap fibroatheroma (TCFA) with superimposed thrombus. Rather than undermining intensive lipid lowering, this case highlights the gap between systemic lipid control and local plaque stabilization: the drug-intervention lag phase (Figure). Figure.Drug-intervention lag phase and multidimensional residual atherosclerotic risk. (Upper panel) Following initiation of intensive lipid-lowering therapy, LDL-C levels decline rapidly, but plaque vulnerability decreases more gradually over time. This temporal dissociation creates a clinically relevant drug-intervention lag phase, during which systemic lipid control may improve despite persistent local plaque vulnerability and continued risk of coronary events. (Lower panel) The transition from vulnerable to stabilized plaque emphasizes the multidimensional nature of residual atherosclerotic risk, including residual plaque, lipid-related, and inflammatory risks. Integrated assessment of plaque features and systemic residual risk may help refine individualized management. HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; TCFA, thin-cap fibroatheroma. Drug-intervention lag phase and multidimensional residual atherosclerotic risk. (Upper panel) Following initiation of intensive lipid-lowering therapy, LDL-C levels decline rapidly, but plaque vulnerability decreases more gradually over time. This temporal dissociation creates a clinically relevant drug-intervention lag phase, during which systemic lipid control may improve despite persistent local plaque vulnerability and continued risk of coronary events. (Lower panel) The transition from vulnerable to stabilized plaque emphasizes the multidimensional nature of residual atherosclerotic risk, including residual plaque, lipid-related, and inflammatory risks. Integrated assessment of plaque features and systemic residual risk may help refine individualized management. HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; TCFA, thin-cap fibroatheroma. Natural history studies show that future coronary events frequently arise from non-flow-limiting lesions with high-risk morphology.4 Serial intracoronary imaging studies suggest that, although LDL-C declines within weeks, structural plaque changes such as plaque regression and fibrous-cap thickening evolve over months.5 Imaging-based studies of PCSK9 inhibitor-associated therapy observed such changes only after prolonged treatment,6 and our prior case report similarly suggested stepwise regression of non-culprit lipid-rich plaque rather than immediate stabilization.7 Accordingly, the case reported by Miura et al.3 should be interpreted not as failure of intensive lipid lowering, but as an illustration of the temporal dissociation between systemic lipid control and local plaque stabilization. Intensive lipid lowering is therefore better understood as a time-dependent process of plaque remodeling than as an immediate shift from vulnerability to stability. Although circulating LDL-C declines quickly, attenuation of lipid burden and rupture-prone morphology lags behind, leaving a period in which biochemical control improves but local plaque vulnerability remains incompletely neutralized. This temporal mismatch reframes residual cardiovascular risk. Residual risk after intensive lipid lowering is multidimensional, encompassing persistent local plaque vulnerability, residual lipid-related risk beyond LDL-C, and residual inflammatory risk.8 Residual plaque risk may be underrecognized because systemic biomarkers are readily measurable and may improve, but plaque morphology is not routinely assessed and may persist or even progress unnoticed. Plaque vulnerability represents the local vascular consequence of systemic biology, expressed as TCFA, a large lipid core, and a wide lipid arc.9 Residual lipid-related risk may also persist through lipoprotein(a), apolipoprotein B-containing particles, and remnant lipoproteins. Risk assessment should therefore extend beyond the achieved LDL-C level alone. The practical challenge is identifying patients most likely to remain vulnerable during this interval. Persistent plaque-level risk may be especially relevant in those with high-risk plaque morphology, recurrent events despite apparently adequate lipid control or high-risk backgrounds such as familial hypercholesterolemia. Residual inflammatory risk also deserves attention: persistent inflammation despite intensive lipid lowering is associated with adverse outcomes in both chronic coronary syndrome and after percutaneous coronary intervention PCI.10,11 Inflammation is not merely a parallel marker but may contribute directly to plaque destabilization, delayed healing, and recurrent thrombosis, helping explain why apparently adequate LDL-C control does not always translate into biological quiescence of high-risk plaques. Clinically, target LDL-C achievement should not be equated with immediate neutralization of coronary risk. In patients at particularly high risk, management may need to incorporate systemic risk markers, including inflammatory activity, together with lesion-level vulnerability and its temporal evolution. Closer follow-up with coronary computed tomography angiography and, when justified, intracoronary imaging may help identify persistent high-risk features despite apparently adequate lipid control, refining individualized risk stratification and management. This does not imply routine invasive surveillance or preventive intervention for all non-flow-limiting plaques. Rather, it supports a tailored approach integrating lesion-level information with the broader clinical context. The PREVENT trial further suggests that, in selected settings, preventive intervention for high-risk non-culprit plaques may provide incremental benefit beyond optimal medical therapy,12 although those findings should be interpreted cautiously. In conclusion, intensive lipid lowering remains indispensable for secondary prevention of CAD, but early biochemical success should not be conflated with immediate plaque stabilization. As illustrated by the case from Miura et al.,3 a clinically important interval may exist during which LDL-C improves while plaque vulnerability persists. This temporal dissociation highlights the need to look beyond achieved LDL-C alone and integrate plaque-level and systemic residual risk when assessing patients with high-risk coronary atherosclerosis. Conflicts of Interest N.T. has received honoraria for lectures from Novartis Pharma. H.I. has received honoraria for lectures from MSD, Kowa Co. Ltd., Amgen, Novartis Pharma and Otsuka Pharma Co. Ltd., and research funding from Mochida Pharmaceutical Co. Ltd. and Kowa Co. Ltd.